TTR and amyloidosis: Tafamidis, an oral, non-NSAID, highly specific TTR stabilizer has emerged as the new standard of care for ATTRV30M and remains the only medicine approved for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy [7].